The league table of network meta-analysis for ORR according to all interventions
| OR 95% CrIs | ||||||
| Bev_DDP | ||||||
| 3.19 (2.11, 4.92)* | DDP | |||||
| 0.85 (0.53, 1.37) | 0.27 (0.22, 0.33)* | Endo_DDP | ||||
| 0.16 (0.05, 0.53)* | 0.05 (0.02, 0.15)* | 0.19 (0.06, 0.59)* | Endo_LBP | |||
| 0.25 (0.09, 0.68)* | 0.08 (0.03, 0.2)* | 0.29 (0.11, 0.75)* | 1.54 (0.35, 6.84) | Endo_NDP | ||
| 0.92 (0.4, 2.03) | 0.29 (0.14, 0.56)* | 1.08 (0.52, 2.18) | 5.69 (2.37, 14.65)* | 3.73 (1.17, 12.04)* | LBP | |
| 0.81 (0.38, 1.71) | 0.25 (0.13, 0.46)* | 0.95 (0.49, 1.81) | 5.06 (1.39, 19.02)* | 3.28 (1.65, 6.76)* | 0.88 (0.35, 2.24) | NDP |
ORs between the included interventions according to the results of network meta-analysis.
Data bolded in black indicate they are from an indirect comparison.
*p<0.05.
Bev_DDP, bevacizumab+cisplatin; CrIs, credible intervals; Endo_DDP, endostar+cisplatin; Endo_LBP, endostar+lobaplatin; Endo_NDP, endostar+nedaplatin; ORR, objective response rate.